Overview

GenVault stores and manages biological samples and genetic material at room temperature, offering a cost- and space-efficient alternative to traditional freezer storage. Its product lineup includes chemically treated papers and plates for collecting and storing samples, plus automated systems for handling, archiving, and retrieving them. The core idea is to stabilize DNA and RNA without refrigeration so samples stay viable over the long term, even in power outages. This differentiates GenVault from competitors by combining ambient-temperature preservation with automated sample management, reducing energy use and freezer maintenance costs. The company aims to provide scalable, reliable biosample storage and management that supports longitudinal research, drug discovery, and clinical diagnostics while cutting environmental and financial costs.

Simplify's Take

What believers are saying

• Andrew Lee appointed Executive Director on August 9, 2023, strengthens biorepository leadership.
• Dry state platform expands to proteins, supporting cell and gene therapy storage.
• Custom-built NJ facility exceeds standards for GXP supplies and high-value vaccines.

What critics are saying

• Thermo Fisher divests GenVault in 2026 to optimize portfolio, disrupting operations.
• Azenta captures 25% more pharma contracts with faster automated retrieval systems.
• Qiagen launches cheaper DNA cards in Q1 2026, eroding room-temperature market share.

What makes GenVault unique

• GenVault stabilizes DNA, RNA, and proteins at room temperature without refrigeration.
• West Deptford facility built in 2017 offers 500,000 cu.ft. hybrid storage solutions.
• GenVault Transportation relocates freezers nationally while maintaining temperature control.

Help us improve and share your feedback! Did you find this helpful?

YesNo